{Reference Type}: Journal Article
{Title}: Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
{Author}: Karacin C;Sunar V;Urakci Z;Yilmaz A;Ayhan M;Ersoy M;Guven DC;Erturk I;Durmus Y;Karacin P;Boran N;Ustun YE;Meydan M;Dogan M;Oksuzoğlu B;Ates O;Karaca M;Uncu D;Ergun Y;Arik Z;
{Journal}: Future Oncol
{Volume}: 20
{Issue}: 4
{Year}: 2024 Feb 8
{Factor}: 3.674
{DOI}: 10.2217/fon-2023-0763
{Abstract}: Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.